Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 6/20 | 0.44 |
| ▸ | ACACA | Q13085 | 6/20 | 0.44 |
| ▸ | PPOX | P50336 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 3/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 2/20 | 0.35 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14609665 | 0.84 | GSK3B (0.43) | ACACBACACAPPOXLRRK2CES1 | |
| SCHEMBL11941316 | 0.81 | ACACB (0.65) | ACACBACACA | |
| SCHEMBL11941306 | 0.78 | DAO (0.39) | ACACBACACANOTUM | |
| SCHEMBL14432147 | 0.78 | ACACB (0.37) | ACACBACACACES1 | |
| SCHEMBL11941309 | 0.77 | ACACB (0.56) | ACACBACACAPPOXNOTUMCES1 | |
| SCHEMBL811828 | 0.76 | PGR (0.45) | ACACBACACA | |
| SCHEMBL11941315 | 0.76 | ACACB (0.46) | ACACBACACALRRK2 | |
| SCHEMBL11949744 | 0.74 | ACACB (0.63) | ACACBACACANOTUMCES1 | |
| SCHEMBL12658142 | 0.73 | ACACB (0.39) | ACACBACACACES1 | |
| SCHEMBL12424882 | 0.71 | PPOX (0.48) | PPOXNOTUMLRRK2CES1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3372580-B1 | METHOD FOR THE PREPARATION OF 1-H-PYRROLIDIN-2,4-DIONE-DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2020-07-22 | — | — | EP | disclosed |
| EP-2668158-B1 | METHOD FOR PRODUCING 1-H-PYRROLIDINE-2,4-DIONE DERIVATIVES | BAYER IP GMBH (DE) | 2018-06-27 | — | — | EP | disclosed |
| US-9272997-B2 | Process for the preparation of 1-H-pyrrolidine-2,4-dione derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-03-01 | — | — | US | disclosed |
| US-9272997-B2 | Process for the preparation of 1-H-pyrrolidine-2,4-dione derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-03-01 | — | — | US | disclosed |
| US-20140371468-A1 | Process for the Preparation of 1-H-pyrrolidine-2,4-dione Derivatives | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | US | disclosed |
| US-20140371468-A1 | Process for the Preparation of 1-H-pyrrolidine-2,4-dione Derivatives | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | US | disclosed |
| US-8859782-B2 | Process for the preparation of 1-H-pyrrolidine-2,4-dione derivatives | BAYER CROPSCIENCE AG (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859782-B2 | Process for the preparation of 1-H-pyrrolidine-2,4-dione derivatives | BAYER CROPSCIENCE AG (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20120190865-A1 | Process for the Preparation of 1-H-pyrrolidine-2,4-dione Derivatives | BAYER CROPSCIENCE AG (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120190865-A1 | Process for the Preparation of 1-H-pyrrolidine-2,4-dione Derivatives | BAYER CROPSCIENCE AG (DE) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190865-A1 | Process for the Preparation of 1-H-pyrrolidine-2,4-dione Derivatives | DHPS, HPD, DOHH | ACACB 4094/4885ACACA 4346/4885PPOX 5/4885 |
| US-20140371468-A1 | Process for the Preparation of 1-H-pyrrolidine-2,4-dione Derivatives | DHPS, HPD, DOHH | ACACB 4094/4885ACACA 4346/4885PPOX 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.